Keytruda is a biologic medication. A biologic is made from parts of living organisms. It’s available only as a brand-name drug. Keytruda isn’t available in a biosimilar form. Biosimilars are ...

The company also has a solid dividend record. Its payouts have increased by 71% in the past decade, and it currently offers a ...

Merck & Co (MSD), Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET ...

Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR) announced “promising” preliminary results from an ongoing ...

Furthermore, Keytruda will lose patent exclusivity in ... It is also expanding it thanks to acquisitions. Its most-recent, brand-new approval of Winrevair, a medicine for pulmonary arterial ...

Keytruda has been the best-selling medicine ... Not everything will make it to market, but I expect many brand-new approvals and label expansions through 2029. There is one crucial headwind ...

Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

Moderna and MSD have initiated a Phase III clinical study to evaluate mRNA-4157 (V940), an investigational individualised ...

developed it and brought it to market in a host of cancer indications under the brand name Keytruda. Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights ...

It's a cancer drug, KEYTRUDA, next year expected to be $30 ... for cancer, which are all brand new markets for cats and dogs, but, obviously, very lucrative in humans. So that's kind of the ...